DelveInsight’s, “Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2023” report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical trials and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report

 

• Over 28+ Relapsing Remitting Multiple Sclerosis companies are evaluating 30+ Relapsing Remitting Multiple Sclerosis pipeline therapies in various stages of development, and their anticipated acceptance in the Relapsing Remitting Multiple Sclerosis market would significantly increase market revenue.

 

• The leading Relapsing Remitting Multiple Sclerosis Companies include Sanofi, RemeGen, RedHill, Biopharma, Polpharma Biologics, Pipeline Therapeutics, Oryzon Genomics, Novartis, Merck, Medsenic, Mapi Pharma, InnoCare Pharma, Immunic, Immune Response BioPharma, HuniLife Biotechnology, GlaxoSmithKline, GeNeuro SA, Genentech (Roche), Emerald Health Pharmaceuticals, Clene, Nanomedicine, Cinnagen, Biogen, Biocad, Atara Biotherapeutics, Apimeds, Antisense Therapeutics, Anokion, AbbVie, and others

 

• Promising Relapsing Remitting Multiple Sclerosis Pipeline Therapies include Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.

 

• The Relapsing Remitting Multiple Sclerosis companies and academics are working to assess challenges and seek opportunities that could influence Relapsing Remitting multiple sclerosis R&D. The Relapsing Remitting Multiple Sclerosis pipeline therapies under development are focused on novel approaches to treat/improve Relapsing Remitting multiple sclerosis.

 

To explore more information on the latest breakthroughs in the Relapsing Remitting Multiple Sclerosis Pipeline treatment landscape of the report, click here @ Relapsing Remitting Multiple Sclerosis Pipeline Outlook

 

Relapsing-Remitting Multiple Sclerosis Overview

Multiple sclerosis (MS) is the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. MS attacks the axons of the central nervous system, which are protected by myelin, commonly known as white matter. Relapsing–remitting MS: the most common form, affecting about 85% of MS patients.

 

Recent Developmental Activities in the Relapsing-Remitting Multiple Sclerosis Pipeline

 

• In March 2022, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients.  The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial. An oral, selective muscarinic M1 receptor antagonist, PIPE-307, is being developed for restoring myelin to treat MS.

 

• In July 2021, InnoCare received $125 million upfront in return for sharing rights to orelabrutinib, an orally-active BTK drug that can cross the blood-brain barrier and penetrate the central nervous system. It is currently in a phase 2 trial for relapsing-remitting multiple sclerosis (RRMS). The deal was back-ended with up to $812.5 million in milestone payments if the drug reaches development, regulatory and commercial milestones, and royalties on any future sales.

 

For further information, refer to the detailed Relapsing-Remitting Multiple Sclerosis Unmet Needs, Relapsing-Remitting Multiple Sclerosis Market Drivers, and Relapsing-Remitting Multiple Sclerosis Market Barriers, click here for Relapsing-Remitting Multiple Sclerosis Ongoing Clinical Trial Analysis

 

Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile

 

• Natalizumab: Polpharma Biologics

Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. Natalizumab is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. In July 2022, Polpharma Biologics announced that the US Food and Drug Administration (FDA) accepted the first-ever Biologics License Application (BLA) for natalizumab, a proposed biosimilar to Tysabri, filed by their collaboration partner Sandoz. The application is for an intravenous (IV) route of administration, with the same dosing regimen, presentation and indication as the reference medicine, Tysabri (natalizumab) – a monotherapy for adult patients with relapsing-remitting multiple sclerosis (RRMS) and adults with moderately-to-severely active Crohn’s disease. A Marketing Approval Application (MAA) for the proposed biosimilar natalizumab was also accepted by the European Medicines Agency (EMA) on 14 July 2022.

 

• Remibrutinib: Novartis

Remibrutinib (LOU064) is a highly selective and potent covalent BTK inhibitor with a potential best-in-class profile and has shown favorable safety based on clinical data established to date. BTK inhibitors are a novel class of therapies that target B-cells and other innate immune cells and prevent inflammation and potentially disease progression in MS.

 

• IMU-838: Immunic AG

Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties.

 

Relapsing-Remitting Multiple Sclerosis Pipeline Therapeutics Assessment

There are approx. 28+ key companies are developing therapies for Relapsing-Remitting multiple sclerosis. The companies which have their Relapsing Remitting multiple sclerosis drug candidates in the most advanced stage, i.e. Preregistration include, Polpharma Biologics.

 

Request a sample and discover the recent advances in Relapsing-Remitting Multiple Sclerosis Ongoing Clinical Trial Analysis and Medications, click here @ Relapsing-Remitting Multiple Sclerosis Treatment Landscape

 

Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report

 

• Coverage- Global

 

• Relapsing-Remitting Multiple Sclerosis Companies- Sanofi, RemeGen, RedHill, Biopharma, Polpharma Biologics, Pipeline Therapeutics, Oryzon Genomics, Novartis, Merck, Medsenic, Mapi Pharma, InnoCare Pharma, Immunic, Immune Response BioPharma, HuniLife Biotechnology, GlaxoSmithKline, GeNeuro SA, Genentech (Roche), Emerald Health Pharmaceuticals, Clene, Nanomedicine, Cinnagen, Biogen, Biocad, Atara Biotherapeutics, Apimeds, Antisense Therapeutics, Anokion, AbbVie, and others

 

• Relapsing Remitting Multiple Sclerosis Pipeline Therapies- Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.

 

• Relapsing-Remitting Multiple Sclerosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Relapsing-Remitting Multiple Sclerosis Market Drivers and Relapsing-Remitting Multiple Sclerosis Market Barriers, click here @ Relapsing-Remitting Multiple Sclerosis Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Relapsing Remitting multiple sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsing Remitting multiple sclerosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Natalizumab: Polpharma Biologics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Orelabrutinib: InnoCare Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. HuL001: HuniLife Biotechnology
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Relapsing Remitting multiple sclerosis  –  Collaborations Assessment- Licensing / Partnering / Funding
18. Relapsing Remitting multiple sclerosis  – Unmet Needs
19. Relapsing Remitting multiple sclerosis  – Market Drivers and Barriers
20. Appendix

 

Got Queries? Find out the related information on Relapsing-Remitting Multiple Sclerosis Mergers and acquisitions, Relapsing-Remitting Multiple Sclerosis Licensing Activities @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/